The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research.

ABSTRACT:

Objective

Despite a multitude of detection and treatment advances in the past 2 decades, prostate cancer remains the second leading cause of deaths due to cancer among men in the United States. Technological evolution and expanding knowledge of tumor biomarkers have invigorated exploration in prostate cancer therapeutics. Prostate-specific membrane antigen (PSMA) was one of the first prostate cancer biomarkers successfully cloned. Since then, it has been characterized as the prototypical cell-surface marker for prostate cancer and has been the subject of intense clinical inquiry. In this article, we review the relevant research in PSMA on the 20th anniversary of its cloning.

Methods and materials

A PubMed search using the keywords "prostate-specific membrane antigen" or "glu

SUBMITTER: Ristau BT 

PROVIDER: S-EPMC3972351 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature